F
Francisco Martínez-Peña
Researcher at Scripps Research Institute
Publications - 7
Citations - 236
Francisco Martínez-Peña is an academic researcher from Scripps Research Institute. The author has contributed to research in topics: Medicine & Chemistry. The author has an hindex of 2, co-authored 2 publications receiving 63 citations.
Papers
More filters
Journal ArticleDOI
Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic
Emily N. Chin,Chenguang Yu,Chenguang Yu,Vincent F. Vartabedian,Ying Jia,Manoj Kumar,Ana M. Gamo,William Vernier,Sabrina H. Ali,Mildred Kissai,Daniel C. Lazar,Nhan T. Nguyen,Laura E. Pereira,Brent Benish,Ashley K. Woods,Sean B. Joseph,Alan Chu,Kristen Johnson,Philipp N. Sander,Francisco Martínez-Peña,Eric Hampton,Travis S. Young,Dennis W. Wolan,Arnab K. Chatterjee,Peter G. Schultz,Peter G. Schultz,H. Michael Petrassi,John R. Teijaro,Luke L. Lairson +28 more
TL;DR: A non-nucleotide, small-molecule STING agonist, termed SR-717, that demonstrates broad interspecies and interallelic specificity and functions as a direct cyclic guanosine monophosphate–adenosine monophile mimetic that induces the same “closed” conformation of STING.
Journal ArticleDOI
HSP90 Inhibition Enhances Cancer Immunotherapy by Modulating the Surface Expression of Multiple Immune Checkpoint Proteins.
Reza Beheshti Zavareh,Reza Beheshti Zavareh,Stephan H. Spangenberg,Ashley K. Woods,Francisco Martínez-Peña,Luke L. Lairson +5 more
TL;DR: It is identified that HSP90 inhibitors robustly decrease PD-L1 surface expression, through a mechanism that appears to involve the regulation of master transcriptional regulators (i.e., STAT-3 and c-Myc).
Journal Article
RECOVER: sequential model optimization platform for combination drug repurposing identifies novel synergistic compounds in vitro
Paul Bertin,Jarrid Rector-Brooks,Deepak Sharma,Thomas Gaudelet,Andrew Anighoro,Torsten Gross,Francisco Martínez-Peña,Eileen L. Tang,S. SurajM,Cristian Regep,Jeremy B. R. Hayter,Maksym Korablyov,Nicholas Valiante,Almer M. van der Sloot,Mike Tyers,Charles Roberts,Michael J. Brownstein,Luke L. Lairson,Jake P. Taylor-King,Yoshua Bengio +19 more
TL;DR: A sequential model optimization search utilising a deep learning model is employed to quickly discover synergistic drug combinations active against a cancer cell line, requiring substantially less screening than an exhaustive evaluation.
Journal ArticleDOI
A Cell Type Selective YM155 Prodrug Targets Receptor-Interacting Protein Kinase 2 to Induce Brain Cancer Cell Death.
Junfeng Bi,Francisco Martínez-Peña,Ellis J Curtis,Nathalia Gazaniga,Paul S. Mischel,Luke L. Lairson +5 more
TL;DR: In this article , a prodrug form of YM155, termed aYM155 was developed, which showed potent cell killing activity against a broad panel of patient-derived GBM cancer stem-like cells, as well as EGFR-amplified and EGFR variant III-expressing (EGFRvIII) cell lines.
Journal ArticleDOI
Reversible Chromism of Tethered Ruthenium(II) Complexes in the Solid State.
TL;DR: In this article , a nonporous materials capable of capturing and releasing HCl reversibly in the crystalline solid state was presented, and the reaction is accompanied by a change in color, is fully reversible, and crystallinity is maintained in both molecular materials.